Skip to main content

Table 1 Inclusion and exclusion criteria

From: Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting

Inclusion criteria diagnosis of NSCLC (adenocarcinoma or LC-anaplastic carcinoma)
  tumour stage IIIb (wet) or IV
  wild-type epidermal growth factor receptor (EGFR)
  first-line therapy with pemetrexed/platin or vinorelbine/platin
  MT with pemetrexed (in the case of remission or stable disease) or, alternatively, with erlotinib (only in the case of stable disease)
  aged between 18 and 90 years
  written informed consent
Exclusion criteria obvious cognitive impairment